Inovio, AstraZeneca terminate cancer vaccine partnership
MedImmune Ltd., the global biologics research and development arm of AstraZeneca (NYSE: AZN), is terminating a cancer therapy partnership it has with Inovio Pharmaceuticals.
The partnership, formed in 2015, gave MedImmune of Gaithersburg, Maryland, exclusive rights to Inovio's experimental DNA-based cancer vaccine, known as INO-3112, for cancers caused by human papillomavirus (HPV) types 16 and 18.
MedImmune renamed the new drug candidate as MED10457 after acquirin g its exclusive rights. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2021 Category: Pharmaceuticals Authors: John George Source Type: news
Accuray touts ASTRO results in breast cancer therapy
Accuray is highlighting clinical results that suggest that early-stage breas...Read more on AuntMinnie.comRelated Reading:
Accuray reports revenue gains for Q1
Accuray to introduce Volo Ultra at ASTRO 2021
Accuray inks collaboration with C-RAD
Accuray promotes prostate cancer research at ESTRO 2021
Accuray lands Radixact install in India (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 25, 2021 Category: Radiology Source Type: news
Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate
Galera Therapeutics stock plunged by more than 70% Tuesday after the Malvern biopharmaceutical firm said its lead experimental cancer therapy failed to meet its primary endpoint in late-stage clinical testing.
The new drug candidate, called GC4419, is under development as a treatment for severe oral mucositis in patients with locally advanced head and neck cancer undergoing radiotherapy.
The trial did not meet its primary endpoint of reduction in the incidence of severe oral mucositis, a condition… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 19, 2021 Category: Biotechnology Authors: John George Source Type: news
Umoja appoints Seagen CEO as its board chairman
Seattle-based Umoja Biopharma on Monday named Clay Siegall as chairman of its board of directors.
Siegall is the CEO and co-founder of Bothell-based Seagen, a biotech company that went public on the Nasdaq in 2001. Siegall co-founded the company in 1998.
"Clay's vast scientific training and wealth of experience, particularly his emphasis on targeted cancer therapies and ability to build a com pany from drug discovery to commercial-stage, will be a crucial part of Umoja's continued growth," Andy… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 18, 2021 Category: American Health Authors: Rick Morgan Source Type: news
Umoja appoints Seagen CEO as its board chairman
Seattle-based Umoja Biopharma on Monday named Clay Siegall as chairman of its board of directors.
Siegall is the CEO and co-founder of Bothell-based Seagen, a biotech company that went public on the Nasdaq in 2001. Siegall co-founded the company in 1998.
"Clay's vast scientific training and wealth of experience, particularly his emphasis on targeted cancer therapies and ability to build a com pany from drug discovery to commercial-stage, will be a crucial part of Umoja's continued growth," Andy… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 18, 2021 Category: Biotechnology Authors: Rick Morgan Source Type: news
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIR... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2021 Category: Pharmaceuticals Source Type: news
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, is pleased to announce that it has received Breakthrough Device Designation for Alpha DaRT ... Devices, Oncology Alpha Tau Medical, Alpha DaRT, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 8, 2021 Category: Pharmaceuticals Source Type: news
Medical College of Wisconsin hires CannonDesign for $100M cancer research center project
The Medical College of Wisconsin hired global firm CannonDesign for what it called Milwaukee ’s first research center dedicated to cancer therapies and treatments.
That MCW Cancer Research Building was first announced in 2019 as an about $100 million, 150,000-square-foot facility. It would expand on the cancer research the Medical College is already doing at the Milwaukee Regional Medic al Center in Wauwatosa. Design work is to start this fall and will last into 2022, according to a Tuesday announcement… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 28, 2021 Category: American Health Authors: Sean Ryan Source Type: news
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
SAN DIEGO, Sept. 22, 2021 -- (Healthcare Sales & Marketing Network) -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, ... Biopharmaceuticals, Oncology Kintara Therapeutics, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 22, 2021 Category: Pharmaceuticals Source Type: news
Acquisition expands research in cancer immunology
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches Boehringer Ingelheim aims to develop novel cancer therapies by leveraging Abexxa ’s unique technology and breakthrough antibody-based drugs. Abexxa ’s focus is on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human leucocyte antigens), enabling the development of cancer immunotherapies potentially benefiting a broader range of patients and cancer types.The addition of Abexxa ’s expertise co...
Source: Boehringer Ingelheim Corporate News - September 21, 2021 Category: Research Source Type: news
Telix applauds NCCN radiotracer update
Injection kit developer Telix applauded the National Comprehensive Cancer Network'...Read more on AuntMinnie.comRelated Reading:
Telix, Kettering to research PSMA radiotracer
Lightpoint, Telix ink collaboration agreement
Telix works with Merck on cancer therapies
Telix Japan names COO
ARTMS, Telix produce PSMA-11 in cyclotron (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 16, 2021 Category: Radiology Source Type: news
Gilead Sciences considered Atlanta, Durham before selecting Raleigh for 275 jobs
The maker of breakthrough HIV, hepatitis C and cancer therapies — as well as the Covid drug remdesivir — snagged nearly $10 million reimbursement incentive and more than $357,000 in community college training incentives from North Carolina. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 16, 2021 Category: American Health Authors: Lauren Ohnesorge Source Type: news
Cell therapy partnership between Bay Area biotechs offers hope to cancer patients
Imagine a world in which physicians can confidently cure cancer.
Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer.
“With cancer therapies,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2021 Category: Pharmaceuticals Authors: Lauren Lawley Head Source Type: news
Heating Up CAR T Cells for Cancer Therapy
Heated gold nanoparticles unleash the therapeutic activity of engineered CAR T cells. (Source: The Scientist)
Source: The Scientist - September 10, 2021 Category: Science Tags: Sponsored Article Source Type: news
B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System
To Downsize Systems and Spread High-precision Irradiation Technology
TOKYO, Sept. 9, 2021 -- (Healthcare Sales & Marketing Network) -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at i... Devices, Oncology, Radiology B dot Medical, proton therapy, compact proton cancer therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 9, 2021 Category: Pharmaceuticals Source Type: news
